MeiraGTx Holdings plc Deferred Tax Assets, in Process Research and Development
MeiraGTx Holdings plc (MGTX) had Deferred Tax Assets, in Process Research and Development of $15.29 million as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-03-30
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $15.29M.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $26.31M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $19.61M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $16.29M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $15.29M 10-K · filed 2026-03-30 |
| 2024-12-31 | $26.31M 10-K · filed 2026-03-30 |
| 2023-12-31 | $19.61M 10-K · filed 2025-03-13 |
| 2022-12-31 | $16.29M 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |